Stephen Knight

Investment Partner

Overview

Gender
male
Investor Type
Investment Partner

Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Steve serves on the Board of Directors of Beam Therapeutics, Genomics plc, Iora Health, Pulmocide, Sana Biotechnology, and Semma Therapeutics. Steve previously served on the boards of several private and public health care companies including Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (HKG:01801), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Proteostasis Therapeutics (NASDAQ: PTI), and Respivert, Ltd (acquired by J&J).

Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.

Jobs

Number of Current Jobs
3
Stephen Knight has 3 current jobs including Board Member at Beam Therapeutics , Board Member at Prime Medicine and Board Of Directors at Blueprint Medicines .
Organization Name Title At Company Start Date End Date
Beam Therapeutics Board Member Detail
Prime Medicine Board Member Detail
Blueprint Medicines Board Of Directors Detail